LRI Investments’s Tarsus Pharmaceuticals TARS Stock Holding History

LRI Investments’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-41	Closed	-$2.88K	–	2004
2026 Q1	$2.88K	Sell	41 -1	-2%	-$70	﹤0.01%	1214
2025 Q4	$3.41K	Buy	+42	New	+$3.14K	﹤0.01%	1112

Other funds holding TARS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

LRI Investments's TARS Position: Q2 2026 in Review

LRI Investments sold out of Tarsus Pharmaceuticals (TARS) in Q2 2026, closing a stake of 41 shares — an estimated $2.88K sold.

LRI Investments first reported a position in TARS in Q4 2025 and held it in 2 quarters. The position peaked at $3.41K in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

LRI Investments reported no remaining Tarsus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
LRI Investments sold 41 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $2.88K.
LRI Investments first reported a position in Tarsus Pharmaceuticals in Q4 2025 and held it in 2 quarters.
LRI Investments's Tarsus Pharmaceuticals position peaked at $3.41K in Q4 2025.
257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on LRI Investments's 13F filing for Q2 2026, filed 14 Jul 2026.